It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The majority of high-grade serous ovarian cancers (HGSCs) are deficient in homologous recombination (HR) DNA repair, most commonly due to mutations or hypermethylation of the BRCA1/2 genes. We aimed to discover how BRCA1/2 mutations shape the cellular phenotypes and spatial interactions of the tumor microenvironment. Using a highly multiplex immunofluorescence and image analysis we generate spatial proteomic data for 21 markers in 124,623 single cells from 112 tumor cores originating from 31 tumors with BRCA1/2 mutation (BRCA1/2mut), and from 13 tumors without alterations in HR genes. We identify a phenotypically distinct tumor microenvironment in the BRCA1/2mut tumors with evidence of increased immunosurveillance. Importantly, we report a prognostic role of a proliferative tumor-cell subpopulation, which associates with enhanced spatial tumor-immune interactions by CD8+ and CD4 + T-cells in the BRCA1/2mut tumors. The single-cell spatial landscapes indicate distinct patterns of spatial immunosurveillance with the potential to improve immunotherapeutic strategies and patient stratification in HGSC.
The tumour microenvironment has not been fully characterised in high-grade serous ovarian cancers (HGSOC). Here, the authors use highly multiplexed imaging to analyse the HGSOC immune microenvironment at spatial and single-cell resolution, with clinically relevant findings for BRCA1/2-mutated tumours.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
2 University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Helsinki University Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666)
3 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Stanford University School of Medicine, Department of Pathology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
5 Duke University Medical Center, Department of Pathology, Durham, USA (GRID:grid.189509.c) (ISNI:0000000100241216)
6 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Brigham and Women’s Hospital, Department of Pathology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Harvard Medical School, Ludwig Center for Cancer Research at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
7 Brigham and Women’s Hospital, Department of Obstetrics and Gynecology and Reproductive Biology, Boston, USA (GRID:grid.62560.37) (ISNI:0000 0004 0378 8294); Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
8 Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
9 Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Ludwig Center for Cancer Research at Harvard, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
10 University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Helsinki University Hospital, Department of Obstetrics and Gynecology, Helsinki, Finland (GRID:grid.15485.3d) (ISNI:0000 0000 9950 5666); Harvard Medical School, Laboratory of Systems Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland (GRID:grid.38142.3c)